Pancreatic Cancer (Ductal Carcinoma)

    Actionable Target Abnormality Prevalence (%) Clinical Experience with Targeted Agent
    KRAS Mutation 71 Trametinib (MEK inhibitor):
    • Phase 1: RR 8% (1)
    • Phase 2: mOS 8.4 vs. 6.7 mo, mPFS 16 vs. 15 wk, ORR 22% vs. 18% for gemcitabine + trametinib vs. gemcitabine + placebo, respectively (2)
    BRCA2 Mutation 10 (3) Olaparib (PARP inhibitor):
    • Phase 2: ORR 22%, SD for ≥8 wk 35% (4)
    PD1 and CSF-1R Variable Cabiralizumab (anti-CSF-1R) + nivolumab (anti-PD-1):
    • Phase 1: Confirmed ORR 13% (5)
    Other topics in Targets by Organ Site